• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Biofrontera AG

    3/14/22 12:15:06 AM ET
    $BFRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRA alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: March 11, 2022
    Accession Number: 0001493152-22-006381
    Submission Type: POS AM
    CIK: 0001712641
    Company Name: Biofrontera AG
    File Number: 333-236021
    Get the next $BFRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BFRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BFRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs

      Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the "Company") (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))), an international biopharmaceutical company, decided today its American Depositary Shares ("ADS") should be delisted from the Nasdaq Capital Market ("Nasdaq") and its reporting obligations with the Securities and Exchange Commission ("SEC") should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Biofrontera AG intends to maintain an amended ADS program on a Level I basis, which will allow investors to continue to hold their securities in the form of ADSs and trade the

      2/14/22 2:05:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG announces mediation results

      Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (OTC:BFFTF) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major shareholder is Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd, Japan. At the upcoming Annual General Meeting of Biofrontera AG on December 14, 2021

      11/19/21 8:45:00 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

      Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S

      11/17/21 5:00:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Biofrontera Ag claimed ownership of 8,000,000 shares

      3 - Biofrontera AG (0001712641) (Reporting)

      10/28/21 9:46:54 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      2/25/22 4:01:31 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      12/21/21 4:01:09 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Biofrontera AG (Amendment)

      SC 13D/A - Biofrontera AG (0001712641) (Subject)

      11/29/21 4:01:24 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    Financials

    Live finance-specific insights

    See more
    • Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

      Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 29%5,379 4,661 15%Gross profit on sales15,761 18,262 (14)%4,680 3,637 29%Research and development costs(4,516)(3,403)33%(1,595)(1,014)57%General and administrative costs(7,557)(6,882)10%(2,004)(2,410)19%S

      11/17/21 5:00:00 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021

      Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021. Conference calls for shareholders and interested investors will be held on Thursday, November 18, 2021, at the following times: In German, November 18, 2021 at 10:00 am CET (4:00 am ET)Dial-in number Germany: +49 69201744220Conference code: 35058739# In English, November 18, 2021 at 2:00 pm CET (8:00 am ET)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference co

      11/9/21 5:45:49 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021

      Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F))) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021. Conference calls for shareholders and interested investors will be held on Friday, August 20, 2021, at the following times: In German, August 20, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: +49 69201744220Conference code: 63828444# In English, August 20, 2021 at 2:00 pm CEST (8:00 am EST)Dial-in number USA: +1 8774230830Dial-in number UK: +44 2030092470Conference code: 78540812# Plea

      8/12/21 8:55:00 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Biofrontera AG

      EFFECT - Biofrontera AG (0001712641) (Filer)

      3/14/22 12:15:06 AM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15F-12B filed by Biofrontera AG

      15F-12B - Biofrontera AG (0001712641) (Filer)

      3/9/22 4:27:42 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Biofrontera AG

      POS AM - Biofrontera AG (0001712641) (Filer)

      3/9/22 2:35:54 PM ET
      $BFRA
      Biotechnology: Pharmaceutical Preparations
      Health Care